- Home
- OGI vs PBYI Comparison
OGI vs PBYI Comparison
Compare OGI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- PBYI
- Stock Information
- Founded
- OGI 2013
- PBYI 2010
- Country
- OGI Canada
- PBYI United States
- Employees
- OGI N/A
- PBYI N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- PBYI Health Care
- Exchange
- OGI Nasdaq
- PBYI Nasdaq
- Market Cap
- OGI 234.5M
- PBYI 263.4M
- IPO Year
- OGI N/A
- PBYI N/A
- Fundamental
- Price
- OGI $1.60
- PBYI $5.16
- Analyst Decision
- OGI
- PBYI Strong Buy
- Analyst Count
- OGI 0
- PBYI 1
- Target Price
- OGI N/A
- PBYI $7.00
- AVG Volume (30 Days)
- OGI 565.8K
- PBYI 414.7K
- Earning Date
- OGI 12-17-2025
- PBYI 11-06-2025
- Dividend Yield
- OGI N/A
- PBYI N/A
- EPS Growth
- OGI N/A
- PBYI 434.29
- EPS
- OGI 0.05
- PBYI 0.97
- Revenue
- OGI $164,107,753.00
- PBYI $238,062,000.00
- Revenue This Year
- OGI $59.31
- PBYI N/A
- Revenue Next Year
- OGI $15.12
- PBYI N/A
- P/E Ratio
- OGI $31.67
- PBYI $5.31
- Revenue Growth
- OGI 50.01
- PBYI 8.63
- 52 Week Low
- OGI $0.85
- PBYI $2.32
- 52 Week High
- OGI $2.08
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- OGI 37.28
- PBYI 52.51
- Support Level
- OGI $1.67
- PBYI $5.00
- Resistance Level
- OGI $1.79
- PBYI $5.61
- Average True Range (ATR)
- OGI 0.09
- PBYI 0.26
- MACD
- OGI -0.04
- PBYI -0.03
- Stochastic Oscillator
- OGI 0.00
- PBYI 21.33
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.